What 5 Analyst Ratings Have To Say About Reata Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Reata Pharmaceuticals (NASDAQ:RETA) has received five analyst ratings in the last quarter, with one being bullish and four somewhat bullish. The average price target is $109.6, compared to the current price of $101.64, implying an upside. The average price target has increased by 17.53% over the past month.
June 28, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reata Pharmaceuticals has received mostly bullish ratings from analysts, with an average price target higher than the current price, suggesting potential upside.
The company has received mostly bullish ratings from analysts, which is a positive sign. The average price target is also higher than the current price, suggesting that analysts believe the stock has potential for growth. This could lead to increased investor interest and a potential increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100